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Extracellular Ca2 is essential for the development of stable
epithelial tight junctions. We find that in the absence of extra-
cellular Ca2, AMP-activated protein kinase (AMPK) activation
and glycogen synthase kinase (GSK)-3 inhibition indepen-
dently induce the localization of epithelial tight junction com-
ponents to the plasma membrane. The Ca2-independent de-
position of junctional proteins induced by AMPK activation and
GSK-3 inhibition is independent of E-cadherin. Furthermore,
the nectin-afadin system is required for the deposition of tight
junction components induced by AMPK activation, but it is not
required for that induced by GSK-3 inhibition. Phosphoryla-
tion studies demonstrate that afadin is a substrate for AMPK.
These data demonstrate that two kinases involved in regulating
cell growth and metabolism act through distinct pathways to
influence the deposition of the components of epithelial tight
junctions.
Polarized epithelial cells possess highly specialized intercel-
lular junctions, including adherens junctions and tight junc-
tions. These cell junctions regulate the paracellular diffusion of
small molecules and restrain the movement of proteins
between the apical and the basolateral membrane compart-
ments (1). A number of studies have demonstrated that extra-
cellular Ca2 is essential for both the development of new junc-
tions (2–4) and the stabilization of mature junctions (5–10).
The cell adhesion molecule E-cadherin (11) enriched at adher-
ens junctions (12) plays a critical role in epithelial cell adhesion
and junction assembly (11, 13–17). The dependence of junction
assembly on Ca2 is likely attributable to the capacity of Ca2 to
stabilize E-cadherin in its adhesive state (18). Antibodies blocking
the adhesion of E-cadherin also inhibit the formation of cell junc-
tions (11, 19). Depletion of E-cadherin expression disrupts the
establishment but not the maintenance of cell junctions (20).
The cytoplasmic tail of E-cadherin contains a binding site for
-catenin (21), which subsequently binds -catenin (22, 23)
and then the actin cytoskeleton (24, 25).
Nectins belong to another family of cell adhesion molecules
that consists of four members (26). The intercellular interac-
tions of nectinmolecules are Ca2-independent. TheC termini
of nectins bind the PDZ domain of afadin (27), which then
binds F-actin (28). Together, the nectins and afadin constitute
another system that organizes adherens junctions coopera-
tively with the cadherin-catenin system in epithelial cells. The
nectin-afadin system can also independently support the for-
mation of weak cell-cell junctions when cadherin-based cell
junctions are absent (29). A recent study further demonstrated
that nectin junctions appear during the earliest stages of epithe-
lial cell morphogenesis and that expression of a dominant neg-
ative form of nectin causes failure of cell polarization and dis-
ruption of tight junction assembly (30).
Tight junction membrane proteins can be recruited to the
cadherin- or nectin-based adhesion sites via the interactions
between a tight junction scaffolding protein, zonula occludens
(ZO)3-1, and either -catenin (31) or afadin (32), respectively.
The association between tight junction components and adhe-
rens junctions mediates the deposition of tight junction pro-
teins to the cell surface in the early steps in tight junction
assembly (33).
Our previous study using Mardin-Darby canine kidney
(MDCK) epithelial cells revealed that AMPK plays a role in the
regulation of epithelial tight junction assembly (34). AMPK is a
serine-threonine kinase involved in the regulation of cell metabo-
lism. Its activity increases with increasing AMP:ATP ratios (35).
ElevatedAMP levels renderAMPKsusceptible to activatingphos-
phorylation by upstream kinases such as LKB1 (36–38).
Activation of LKB1 induces a series of epithelial cell polar-
ization events, including the deposition of junctional proteins
to a belt surrounding an apical like region. These events appear
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to be independent of cell-cell contact and thus of intercellular
interactions of adhesion (39). Interestingly, two recent studies
found that localized activation of LKB1 represents an early sig-
nal for axon initiation in undifferentiated neurons (40, 41),
which constitutes a critical step in neuronal polarization (42).
The signal initiated by LKB1 activation induces inactivation of
GSK-3, and this event appears to be essential for axon elonga-
tion (43). GSK-3 is a serine-threonine kinase found ubiqui-
tously in eukaryotes (44, 45), which plays important roles in
many biological processes, ranging from the Wnt signaling
pathway to astrocyte migration (46, 47).
In this study, we report for the first time that GSK-3 is also
involved in regulating the deposition of epithelial cell junction
components. We determined that AMPK activation and
GSK-3 inhibition exert their effects on Ca2-independent
deposition of tight junction proteins via independent pathways.
We also identified afadin as a substrate for AMPK. Thus, our
study demonstrates that alterations in the activities of two
kinase pathways can lead independently to the deposition of
tight junction components without the participation of extra-
cellular Ca2 or of the Ca2-dependent epithelial cell adhesion
machinery.
EXPERIMENTAL PROCEDURES
Plasmids and Construct—pSUPER plasmids containing
short hairpin interfering RNA sequences targeting canine
E-cadherin, cadherin-6, and luciferase (served as a transfec-
tion control) were kindly provided by Dr. Ian Macara, Uni-
versity of Virginia. Detailed information about the prepara-
tion of these constructs was reported previously (20). For the
shRNA construct targeting afadin, the E-cadherin RNAi
sequences in the pSUPER plasmid were substituted by afa-
din RNAi sequences 5-GCATGGATGCTGAGACTTA-3
(clone 2) and 5-GACAATCCTGCTGTCTACC-3 (clone
5). Details of afadin shRNA construct preparation are avail-
able upon request.
Antibodies—Sheep anti-1-AMPK was kindly provided by
Dr. D. Grahame Hardie (University of Dundee). Rabbit anti-
PATJ and rabbit anti-PAR3 were kindly provided by Dr. Ben
Margolis (University of Michigan). Rabbit anti-pACC (Ser79),
anti-pan--AMPK, anti-pAMPK (Thr172), and anti-p--
catenin (Ser33/Ser37/Thr41) were purchased from Cell Signal-
ing. Rabbit anti-ZO-1, anti-occludin, and anti-claudin-1 were
purchased from Zymed Laboratories Inc.. Mouse anti-E-cad-
herin clone 36 was purchased from BD Biosciences. Rhoda-
mine-conjugated goat anti-rabbit IgG was purchased from
Chemicon. Alexa Fluor 488-conjugated goat anti-mouse IgG
and Alexa Fluor 488-conjugated goat anti-rabbit IgG were
purchased from Molecular Probes. HRP-conjugated goat anti-
mouse IgG andHRP-conjugated goat anti-rabbit IgGwere pur-
chased from Jackson ImmunoResearch. Rabbit anti-human-1-
afadin and HRP-conjugated donkey anti-sheep IgG were
purchased from Sigma. All commercially available antibodies
were used according to the manufacturers’ instructions.
Cell Culture and Transfection—MDCK cells were main-
tained in -MEM (Invitrogen) supplemented with 10% fetal
bovine serum (Invitrogen), 2 mM L-glutamine (Invitrogen), 50
units/ml penicillin (Invitrogen), and 50 g/ml streptomycin
(Invitrogen). Cells were grown in a humidified incubator at
37 °C and 5% CO2 atmosphere.
To transiently transfect pSUPER plasmids encoding shRNA
sequences targeting E-cadherin, cadherin-6, afadin, and lucif-
erase into MDCK cells, an Amaxa nucleofector was utilized.
The detailed protocols for transfecting MDCK cells using an
Amaxa device have been previously reported (48).
Establishment of AMPK Knockdown Stable Cell Lines—Se-
quences targeting the canineAMPK1 subunitwere subcloned
into pLH1, a derivative of the pSUPER plasmid. Plasmids were
transfected with pVSVG into HEK-G2 cells for lentivirus pack-
aging. Subconfluent MDCK cells were then infected with the
resultant lentivirus. Selection and maintenance of stable
MDCK cell clones were performed in -MEM containing 4
g/ml puromycin (Sigma). Clones were screened for reduced
expression levels of AMPK1 subunit byWestern blot analysis.
An empty pLH1 plasmid was also packaged into lentivirus, and
a pooled control MDCK cell line was established by infection
with this lentivirus. The sequence chosen for targeting AMPK
1 subunit was 5-GCAGAAGTTTGTAGGGCAATT-3.
Calcium Switch—MDCK cells were grown on plastic (for
Western blot analysis) or coverslips (for immunofluorescence)
in -MEM containing 1.8 mM calcium (high calcium medium,
HCM) until they formed a confluent monolayer. Cells were
then washed twice with minimum essential medium for sus-
pension culture (S-MEM, Invitrogen) and incubated in S-MEM
supplementedwith 5% dialyzed fetal bovine serum (Invitrogen)
(low calciummedium, LCM). Cells were incubated in LCM for
16 h before being switched back to HCM for the indicated
times.
Immunofluorescence and Quantification of ZO-1 Staining—
Cells on coverslips were washed three times with cold PBS and
fixed in 100% methanol at 20 °C for 5 min. Cells were then
permeabilized in 0.3% Triton X-100, 0.15% BSA (permeabiliza-
tion buffer) in PBS for 15min at room temperature and blocked
in goat serum dilution buffer (GSDB, 16% goat serum (Invitro-
gen), 20 mM sodium phosphate, pH 7.4, 450 mM NaCl, 0.3%
TritonX-100) for 30min at room temperature. Cells were incu-
bated in primary antibody diluted 1:200 in GSDB for 1 h at
room temperature, then immersed three times in permeabili-
zation buffer, and then incubated for 1 h in secondary antibody
diluted 1:200 in GSDB. Cells were then rinsed three times in
PBS before mounting in Vectashield (Vector Laboratories).
Cells were visualized on a Zeiss Axiophot fluorescence micro-
scope equippedwith aZeissAxioCamHRmCCDcamera. Con-
trast and brightness settings were chosen so that all pixels were
in the linear range. Pictures were taken in the focal plane in
which the most strands of tight junction components were
visualized.
To quantify the mean ZO-1 length per cell, four fields were
randomly selected from each coverslip, and the total length of
ZO-1 at the cell periphery in each field was manually outlined,
followed by length measurement with ImageJ software. Cell
numbers were counted for each field, and the mean ZO-1
length per cell was calculated. Statistical analysis was per-
formed using the two-tailed Student’s t test. In each case, the
data presented are representative of at least two or three inde-
pendent experimental repetitions.
Calcium-independent Junction Deposition
16880 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 19•MAY 13, 2011









Western Blot—Cells were lysed on ice in kinase lysis buffer
(250 mM sucrose, 20 mM Tris-HCl, pH 7.4, 50 mMNaCl, 50 mM
NaF, 5 mM sodium pyrophosphate, 1 mM Na3VO4, 2 mM fresh
DTT, 1% Triton X-100) for 30 min. Cell lysate was centrifuged
at 15,000 rpm at 4 °C for 10 min. Supernatant was then col-
lected for Western blot. Proteins were resolved with 8% SDS-
PAGE using standard protocols. The protein was electropho-
retically transferred to nitrocellulose membranes (Bio-Rad)
and blocked with milk solution (150 mM NaCl, 20 mM Tris, 5%
milk (w/v), 0.1% Tween (v/v), pH 7.5) to quench nonspecific
protein binding. The blocked membranes were probed with
primary and secondary antibodies diluted in the milk solution,
and the bands were visualized with the enhanced chemilumi-
nescence kit (Amersham Biosciences).
AMPK in Vitro Phosphorylation Assay—Each AMPK in vitro
phosphorylation assay included a pre-determined amount of
immunoprecipitated proteins of interest immobilized on pro-
tein A-agarose beads (no more than 20 l of beads), 1 Ci of
[-32P]ATP (freshly purchased from PerkinElmer Life Sci-
ences), 50MATP (Sigma), 100MAMP (Sigma), and 50 ng of
recombinant AMPK 112 protein complex (Cell Signaling).
The assaymixtures were then incubated for 15min at 37 °C in a
solution containing 5 mM MOPS, pH 7.2, 2.5 mM -glycero-
phosphate, 1 mM EGTA, 0.4 mM EDTA, 5 mM MgCl2, and 50
M DTT. The reactions were terminated by incubating mix-
tures at 100 °C for 5 min. The proteins of interest were then
eluted from the beads by incubating with SDS sample buffer at
60 °C for 5 min. The proteins were separated by SDS-PAGE,
after which the gel was dried, and the radioactive signals on the
gel were revealed by autoradiography.
SILAC Labeling and LC-MS/MS Analysis—MDCK cell lines
were passaged at 10% confluence onto 10-cm plates in 10 ml of
heavy (0.1 mg/ml L-lysine-13C6 and 0.025 mg/ml L-arginine-
13C615N4) or light (normal) SILAC media. Cells were grown to
confluence and then replated at 10% confluence, still in
heavy or light medium, with cell numbers normalized
between heavy and light conditions. After treatments, heavy
and light cell lysates were prepared as a 1:1 mixture accord-
ing to protein concentration, and native afadin was then
immunoprecipitated.
Afadin proteins purified via immunoprecipitation and SDS-
PAGE were subjected to in-gel tryptic digestion. Following
digestion, total afadin peptides were subjected to titanium
dioxide (TiO2) enrichment to separate phosphopeptide
(enriched) and nonphosphopeptide (flow-through) fractions
for LC-MS/MS analysis.
Protein identification and SILAC quantitation were batch-
processed usingMascot Daemon (version 2.2.107, ) andMas-
cot Distiller (version 2.3.0.0) from Matrix Science. Data base
searches were conducted using our in-house Mascot Server
(version 2.3.0), which has the latest quantitation Toolbox
update.
RESULTS
Inhibition of GSK-3 Induces Ca2-independent Deposition
of Junction Components—In the MDCK epithelial model sys-
tem, low concentrations of extracellular Ca2 disrupt intercel-
lular junctions (49), and the restoration of high Ca2 concen-
trations induces the deposition of junction proteins to the
plasma membrane. This manipulation is referred to as a “Ca2
switch” (49). We first sought to determine whether the activity
of GSK-3 influences this process.
We cultured MDCK cells to confluency in high Ca2
medium (1.8 mM Ca2, HCM) and then incubated them in low
Ca2medium (5 MCa2, LCM) for 16 h. At 30 min and 1 and
2 h after the reintroduction of HCM, cells were lysed in the
presence of phosphatase inhibitors, followed by aWestern blot
analysis. To examine the activity of GSK-3, we used an anti-
body specifically recognizing -catenin phosphorylated on res-
idues Ser33/Ser37/Thr41. These residues were demonstrated to
be phosphorylated by GSK-3 (50). Thus, the extent of their
phosphorylation indirectly reflects the in situ level of GSK-3
activity. We found that, despite a constant level of total
-catenin, the levels of phosphorylated-cateninwere reduced
in cells lysed after the addition of HCMas compared with those
detected in cells maintained in LCM, suggesting decreased
GSK-3 activity during Ca2-induced epithelial polarization
(Fig. 1A). To determine whether the decreased levels of
-catenin phosphorylation were attributable instead to the
activation of phosphatases during the calcium switch, we
treatedMDCK cells subjected to a calcium switch with okadaic
acid, which inhibits a broad spectrum of phosphatases. We
found that despite an overall increase in -catenin phosphory-
lation, the levels of phosphorylated-cateninwere still reduced in
cells during the calcium switch (supplemental Fig. S1A), sug-
gesting that the activation of phosphatases did not cause the
decrease in -catenin phosphorylation. GSK-3 was reported
to be inhibited by Ser9 phosphorylation (51).We did not detect
any change in Ser9 phosphorylation during the Ca2 switch
using an antibody recognizingGSK-3phosphorylated on Ser9,
suggesting that Ser9 phosphorylation is not responsible for
GSK-3 inhibition during this process (Fig. 1A).
To inhibit GSK-3 pharmacologically, we treated MDCK
cells with theGSK-3 inhibitors (52) 10MSB216763 or 20mM
LiCl for 1 h and found that both treatments decreased
-catenin phosphorylation compared with the treatments with
DMSO vehicle control or with 20 mM NaCl, which reproduces
the osmolarity and tonicity effects of LiCl (Fig. 1B). These data
confirm that SB216763 and LiCl effectively inhibit GSK-3 in
the MDCK cell system. We then investigated the effects of
GSK-3 inhibition on the deposition of tight junction proteins
by examining the time course of the localization of ZO-1 during
Ca2 switch in the presence or absence of GSK-3 inhibitors,
and we found that ZO-1 deposition is significantly accelerated
in the cells incubated in the presence of SB216763 or LiCl, com-
paredwith those incubated inDMSOor inNaCl (supplemental
Fig. S1,B andC), suggesting that GSK-3 inhibition accelerates
the deposition of junction proteins during Ca2-induced junc-
tion assembly.
Intriguingly, we noticed that in MDCK cells pretreated with
GSK-3 inhibitors, tight junction proteins were relocalized to
the sites of cell-cell contact even before the reintroduction of
Ca2. We found that the deposition of ZO-1 occurs in LCM in
the presence of 10 M SB216763 or 20 mM LiCl but not in the
presence of DMSO or NaCl (Fig. 1, C and D). We observed
fragmentary strands of ZO-1 on plasma membranes as early as
Calcium-independent Junction Deposition
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FIGURE 1. Inhibition of GSK-3 induces Ca2-independent deposition of junction components. A, confluent MDCK cells were incubated in LCM for 16 h and
then switched back to HCM for the indicated times. Cell lysates were probed with the indicated antibodies in aWestern blot analysis. B, confluent MDCK cells were
treatedwithDMSO, 10MSB216763, 20mMNaCl, or 20mMLiCl for 2 h. Cell lysateswereprobedwith the indicated antibodies in aWesternblot analysis.C, confluent
MDCKcellswere incubated in LCM for 16h followedby replacementof themediawith fresh LCMsupplementedwithDMSO, 10MSB216763, 20mMNaCl, or 20mM
LiCl. Cells were fixed at the indicated time points after the replacement ofmediumand immunostained for ZO-1. Bar, 30m.D, quantification of ZO-1 relocalization
to cellmembrane inC. Data are representative of three independent experiments (n 3). Error bars representmeans S.D. ZO-1 lengthper cell iswithin eachof the
four randomlypickedviewfields. Theasterisksdenotesignificantdifference in the indicatedpairs (p0.05)byStudent’s t test.E,MDCKcellswere treatedasdescribed
in C, except that they were instead immunostained for occludin. Bar, 30 m. F, quantification of occludin relocalization to cell membrane in E. Error bars represent
meansS.D. foroccludin lengthpercellwithineachof the four randomlypickedviewfields.Theasterisksdenotesignificantdifference in the indicatedpairs (p0.05)
by Student’s t test.G, confluentMDCK cells were incubated in LCM for 16 h followed by replacement of themediawith fresh LCM supplementedwith the indicated
concentrations of different test reagents. Cells were fixed 2 and 10 h after the medium change and immunostained for ZO-1. Bar, 30 m. H, quantification of ZO-1
relocalizationtocellmembrane inG.Dataare representativeof two independentexperiments (n2).Errorbars representmeansS.D. forZO-1 lengthpercellwithin
each of the four randomly picked view fields. The asterisks denote significant differences in the indicated pairs (p 0.05) by Student’s t test.
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1 h and throughout up to 4 h of SB216763 or LiCl treatment.
However, the ZO-1 strands failed to becomemore consolidated
and morphologically organized with further SB216763 or LiCl
incubation. Instead, most of the ZO-1 strands disappeared at
8 h of continued treatment. These results appear to contradict
the widely accepted notion that extracellular Ca2 is required
to initiate the deposition of junction components (2–4). Thus,
we next studied several different proteins associated with the
tight junction to assess the generality of this observation. We
examined the distribution of occludin, a membrane protein
that is essential for the integrity of tight junctions. Similar to
what was observed with ZO-1, we found that, in cells treated
with SB216763 or LiCl, fragmentary strands of occludin were
detectable on the cell membrane, primarily at sites of apparent
cell-cell contact. Most of these occludin strands disappear after
prolonged incubation for 10 h (Fig. 1, E and F). In addition,
following the treatment with SB216763 or LiCl in LCM, we
observed fragmentary strands of PATJ and PAR-3, both of
which are components of polarity complexes that are relocal-
ized to the plasma membrane during junction assembly. These
proteins were diffusely organized following DMSO or NaCl
treatments (supplemental Fig. S1D). We also investigated
whether or not these fragmentary junction components
became tightly associated with the actin cytoskeleton. To begin
to assess this possibility, wemade use of a TritonX-100 extract-
ability assay (53). We separated cell lysates into Triton-soluble
and Triton-insoluble fractions. This latter pool is thought to
include proteins that are strongly associated with the cytoskel-
eton. We did not detect any significant transition of the junc-
tion components ZO-1, occludin, or claudin from the Triton-
soluble pool into the Triton-insoluble pool, suggesting that
these proteins had not yet become tightly associated with the
actin cytoskeleton in response to 2 h ofGSK-3 inhibition (sup-
plemental Fig. S1E). We did not detect any significant increase
in the transepithelial electrical resistance in cells treated for 2 h
with GSK-3 inhibitors (data not shown), presumably because
the nascent junction-related structures that we observed were
incomplete and did not produce tight seals.
We next sought to determine how different concentrations
of GSK-3 inhibitors would affect the extent and the duration
of the Ca2-independent deposition of junction components.
We treated MDCK cells maintained in LCM with the original
(10 M SB216763 or 20 mM LiCl) or quadrupled (40 M
SB216763 or 80 mM LiCl) concentrations of GSK-3 inhibitors
for both 2 and 10 h. After 2 h of treatment, we observed a
significant increase in the number and length of ZO-1 strands
on plasma membranes with the higher doses of the inhibitors.
After 10 h of treatment with either of these high dose GSK-3
inhibitors, substantial numbers of ZO-1 strands were still
retained on the plasma membrane, whereas most of the ZO-1
strands disappeared from plasma membrane in cells treated
with the original concentrations of GSK-3 inhibitors (Fig. 1,G
and H). We found similar results when we stained the cells for
occludin (supplemental Fig. S1, F and G), confirming that
higher concentrations of GSK-3 inhibitors enhance both the
extent and the duration of the Ca2-independent deposition of
junction components.
Our previous study has shown thatAMPKactivation induces
Ca2-independent deposition of junction components to the
sites of cell-cell contact (34). We found that treating cells with
higher concentrations of the AMPK activator, AICAR, also
enhance both the extent and the duration of the Ca2-inde-
pendent deposition of junction components, as compared with
that detected in cells treated with lower AICAR concentrations
(Fig. 1, E–H).
Inhibition of GSK-3 Delays the Withdrawal of Junction
Components from the PlasmaMembrane uponCa2Depletion—
Depletion of Ca2 from the medium causes disassembly of
cell-cell junctions in polarized epithelial cells, and the junction
components become diffusely distributed throughout the
cytoplasm. We sought to determine whether inhibition of
GSK-3 delays this process.We pretreated confluent polarized
MDCK cells cultured in HCM with GSK-3 inhibitors (10 M
SB216763 or 20 mM LiCl) for 1 h and then substituted HCM
with LCM, in the continued presence of these inhibitors. Cells
were fixed immediately or 4 or 10 h following the medium
change and were then immunostained for ZO-1. After both 4
and 10 h of Ca2 depletion, we observed significantly more
ZO-1 organized on the plasmamembranes of cells treated with
SB216763 or LiCl than on those of cells treated with DMSO or
NaCl (Fig. 2). We also studied the distribution of occludin dur-
FIGURE 2. Inhibition of GSK-3 delays the withdrawal of junction pro-
teins from the plasma membrane upon Ca2 depletion. A, confluent
MDCK cellswere incubated inHCMwithDMSO, 10MSB216763, 20mMNaCl,
or 20mM LiCl for 1 h before theywere switched to LCM in the presence of the
aforementioned test reagents. Cells were fixed 4 and 10 h after the medium
change and immunostained for ZO-1. Bar, 30m. B,quantification of ZO-1 on
the cell membrane in A. Data are representative of three independent exper-
iments (n  3). Error bars represent means  S.D. for ZO-1 length per cell
within each of the four randomly picked view fields. The asterisks denote
significant differences in the indicated pairs (p 0.05) by Student’s t test.
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ing these treatments, and we found that significantly more
occludin strands were retained on the plasma membrane after
10 h of Ca2 depletion when the cells were treated with
SB216763 or LiCl, compared with cells treated with DMSO or
NaCl (supplemental Fig. S2). Taken together, these results
demonstrate that GSK-3 inhibition delays the withdrawal of
junction components from the plasma membrane when extra-
cellular Ca2 is depleted.
Activation of AMPK and Inhibition of GSK-3 Synergistically
Induce Ca2-independent Deposition of Junction Components
via Different Pathways—Because both AMPK activation and
GSK-3 inhibition induce similar effects on the deposition of
junction components, we sought to determine whether these
two kinases function in the same pathway. We first examined
whether AMPK activation leads to GSK-3 inhibition or vice
versa.AMPK is activated by phosphorylation on residueThr172,
and activated AMPK phosphorylates its substrate acetyl-CoA
carboxylase (35). The phosphorylation status of AMPK and
acetyl-CoA carboxylase is widely used as an indicator of AMPK
activity. We treated MDCK cells with 1 mM AICAR for 2 h and
found significantly higher levels of both phosphorylatedAMPK
and phosphorylated acetyl-CoA carboxylase, which confirms
that AMPK is activated. We then examined the levels of phos-
phorylated-catenin and found no significant change, suggest-
ing that GSK-3 is not inhibited by AMPK activation (Fig. 3A).
We next performed a reciprocal experiment by treatingMDCK
cells with 10 M SB216763 or 20 mM LiCl for 1 h and then
examining the levels of AMPK activity. We observed signifi-
cantly lower levels of -catenin phosphorylation but no change
in the phosphorylation of either AMPK or acetyl-CoA carboxy-
lase, suggesting that AMPK is not activated by GSK-3 inhibi-
tion (Fig. 3A).
We then sought to determine whether the effects of AMPK
activation and GSK-3 inhibition on Ca2-independent depo-
sition of junction components are synergistic. If GSK-3 inhi-
bition could further promote the deposition of junction com-
ponents when the effects of AMPK activation on this process
are maximized, it would constitute a strong argument that the
effects of AMPK activation and GSK-3 inhibition are syner-
gistic and that they are unlikely to function in the same path-
way. We found that the effects of AMPK activation are satu-
rated at 4 mMAICAR (supplemental Fig. S3,A and B). We then
combined GSK-3 inhibitors (10 M SB216763 or 20 mM LiCl)
with 4 mM AICAR in LCM and treated Ca2-depleted MDCK
cells for 2 h.Wewere able to detect significantlymore extensive
ZO-1 or occludin strands on the plasma membrane with the
combination of GSK-3 inhibitors and AICAR than were
observed with the DMSO or NaCl in combination with AICAR
(Fig. 3, B–D) These data indicate that GSK-3 inhibition fur-
ther promotes Ca2-independent deposition of junction com-
ponents under conditions in which AMPK effects are maxi-
mized, suggesting that these two molecules function
synergistically via different pathways.
If AMPK and GSK-3 employ different pathways to induce
Ca2-independent deposition of junction components, then
elimination ofAMPKactivity should not influence the effects of
GSK-3 inhibition. To test this hypothesis, we introduced
AMPK shRNA into MDCK cells and generated stable cell lines
(4-2 and 4-15) in which AMPK expression is reduced by 90%
comparedwith those of control cell lines (P7 and LRT) (supple-
mental Fig. S3C). We found that AICAR is much less effective
in inducing Ca2-independent deposition of junction compo-
nents in AMPK knockdown cells, as evidenced by many fewer
ZO-1 strands relocalized to the sites of cell-cell contact than
those observed in control cell lines. However, when we treat
AMPK knockdown cells with GSK-3 inhibitors, we detected
levels of ZO-1 deposition similar to those found in control cell
lines (Fig. 3, E and F). Similar results were also observed when
we stained the cells for occludin (supplemental Fig. S3, D and
E). We conclude that the effects of GSK-3 inhibition on the
deposition of junction components are not affected by reduced
AMPK activity, further suggesting that AMPK activation and
GSK-3 inhibition induce Ca2-independent deposition of
junction components via different pathways.
Activation of AMPK and Inhibition of GSK-3 Induce Depo-
sition of Junction Components Independent of E-cadherin—Ep-
ithelial cells adhere to their neighbors via E-cadherin, which
requires extracellular Ca2 to stabilize it in its adhesive state.
Blockade of adhesion inhibits the formation of the epithelial
junction complex (18). Because AMPK activation and GSK-3
inhibition induce deposition of junction components inde-
pendent of extracellular Ca2, we sought to determine whether
this process is also independent of E-cadherin.
To test the involvement of E-cadherin, we used shRNA con-
structs targeting both E-cadherin and the kidney-specific cad-
herin-6, as well as a control construct (kindly provided by Dr.
Ian Macara, University of Virginia). The efficacy of these con-
structs has been previously demonstrated (20). We transiently
transfected these constructs intoMDCKcells, cultured the cells
for 48 h in HCM, and found that more than 90% of E-cadherin
was eliminated (supplemental Fig. S4A). These cadherin knock-
down cells and control cells were cultured in LCM for 16 h
before being treated with 1 mMAICAR, 10 M SB216763, or 20
mM LiCl. We found no significant difference in the amount of
ZO-1 or occludin that was relocalized to plasma membrane in
cadherin knockdown cells versus control cells, suggesting that
FIGURE 3. AMPK activation and GSK-3 inhibition synergistically induce Ca2-independent deposition of junction components via different path-
ways. A,MDCK cells were treated with 1 mM AICAR, DMSO, 10 M SB216763, 20 mM NaCl, or 20 mM LiCl for 2 h. Cell lysates were probed with the indicated
antibodies in aWestern blot analysis. ctrl, control. B, confluentMDCK cells were incubated in LCM for 16 h followed by the replacement of themediawith fresh
LCMsupplementedwith the combinationof 4mMAICARandDMSO, SB216763, NaCl, or LiCl. Cellswere fixed 2h after themediumchange and immunostained
for ZO-1 and occludin. Bar, 30m. C andD, quantification of ZO-1 and occludin relocalization, respectively, to cell membrane in B. Data are representatives of
two independent experiments (n 2) for each protein. Error bars represent means S.D. for strand length per cell within each of the four randomly picked
fields of view. The asterisks denote significant differences in the indicated pairs (p 0.05) by Student’s t test. E, confluent AMPK knockdown stableMDCK cells
and confluent control cells were incubated in LCM for 16 h followed by the replacement of the media with fresh LCM supplemented with DMSO, SB216763,
NaCl, LiCl, or AICAR. Cells were fixed 2 h after the medium change and immunostained for ZO-1. Bar, 30 m. F, quantification of ZO-1 relocalization to cell
membrane in E. Data are representative of three independent experiments (n 3). Error bars representmeans S.D. for ZO-1 length per cell within each of the
four randomly picked view fields. p values from Student’s t test are noted in the figure.
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AMPK activation andGSK-3 inhibition induce the deposition
of junction components independent of E-cadherin involve-
ment (Fig. 4, A and B, and supplemental Fig. S4, B and C). By
doubly staining cell samples with antibodies directed against
E-cadherin and ZO-1, we also noticed that ZO-1 was relocal-
ized to the plasma membrane even in cells where E-cadherin
expression was barely detectable (Fig. 4C).
We have demonstrated in a previous report that AMPK is
activated during extracellular Ca2-induced junction assembly
(34). Because E-cadherin is not required in Ca2-independent
deposition of junction components induced by AMPK activa-
tion, we sought to determine whether extracellular Ca2 could
induce the deposition of junction components in cells where
E-cadherin ismissing.We transfectedMDCKcells with shRNA
constructs targeting cadherins and then subjected these cells to
a Ca2 switch. We found that the introduction of extracellular
Ca2 induced a modest but significant relocalization of junc-
tion components to the sites of cell-cell contact in cadherin
knockdown cells. We compared the level of the deposition of
junction components induced by extracellular Ca2 with that
FIGURE 4. Activation of AMPK and inhibition of GSK-3 induce deposition of junction components independent of E-cadherin. A, MDCK cells trans-
fected with E-cadherin or control shRNAs were incubated in LCM for 16 h followed by replacement of the media with fresh LCM supplemented with 1 mM
AICAR, 20 mM NaCl, or 20 mM LiCl. Cells were fixed 2 h after the medium change and immunostained for ZO-1. Bar, 30 m. Luc-ctrl, luciferase control.
B, quantification of ZO-1 relocalization to cell membrane inA. Data are representative of three independent experiments (n 3). Error bars representmeans
S.D. for ZO-1 length per cell within each of the four randomly picked view fields. C,MDCK cells transfected with E-cadherin or control shRNAs were incubated
in LCM for 16 h followed by replacement of the media with fresh LCM supplemented with 20 mM LiCl. Cells were fixed 2 h after the medium change and
immunostained for ZO-1 andE-cadherin.Bar,30m.D,MDCKcells transfectedwith E-cadherin or control shRNAswere incubated in LCM for 16h.Mediumwas
replaced by fresh LCM supplemented with AICAR or HCM. Cells were fixed 2 h after the medium change and immunostained for ZO-1. Bar, 30 m. E, quanti-
fication of ZO-1 relocalization to cell membrane in D. Data are representative of two independent experiments (n 2). Error bars represent means S.D. for
ZO-1 length per cell within each of the four randomly picked view fields. F,MDCK cells transfected with E-cadherin or control shRNAs were incubated in LCM
for 16 h and then switched back to HCM for the indicated times. Cell lysates were probed with the indicated antibodies in a Western blot analysis.
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induced by theAICAR treatment in the absence of extracellular
Ca2. We found that in cells where E-cadherin is depleted,
these two regimens induced comparable levels of deposition of
junction components (Fig. 4,D andE). It is interesting to note in
this context that the Ca2 switch led to AMPK activation in the
E-cadherin knockdown cells, as revealed by Western blotting
for phosphorylated AMPK (Fig. 4F). Taken together, these data
are consistent with the interpretation that the E-cadherin-in-
dependent deposition of junction components stimulated by
Ca2 switch could be attributable to Ca2 switch-induced acti-
vation of AMPK.
Afadin Is Required for AMPK Activation, but Not GSK-3
Inhibition, to Induce the Deposition of Junction Components—
The nectin-afadin protein complex mediates cell adhesion
independent of the cadherin-cateninmechanism. The intercel-
lular interaction between nectin molecules does not require
extracellular Ca2. Because the deposition of junction compo-
nents induced by eitherAMPK activation orGSK-3 inhibition
is independent of extracellular Ca2, we sought to investigate
whether these processes are mediated by the nectin-afadin
system.
To assess the involvement of the nectin-afadin system, we
examined the Ca2-independent deposition of junction com-
ponents in cells lacking a functional nectin-afadin complex.
Nectins are a family of membrane proteins consisting of multi-
ple members, with each member existing in a variety of splice
isoforms (26). The diversity of nectins makes it difficult to effi-
ciently eliminate their expression by the RNAi technique. Each
nectin isoform, however, is linked to the actin cytoskeleton via
their interaction with afadin. Therefore, knocking down afadin
functionally decreases the availability of the nectin-afadin sys-
tem to mediate cell-cell adhesion. We used shRNA constructs
targeting afadin and the aforementioned control construct.We
transiently transfected these constructs into MDCK cells, cul-
tured these cells for 48 h in HCM, and found that about 80% of
afadin was eliminated (supplemental Fig. S5A). These afadin
knockdown cells and control cells were cultured in LCM for
16 h before they were treated with 1 mM AICAR, 10 M
SB216763, or 20 mM LiCl. We found that in afadin knockdown
cells, there was no significant Ca2-independent ZO-1 or
occludin relocalization induced by AICAR treatment. In con-
trol cells, however, AICAR treatment induced significantly
more relocalization of ZO-1 and occludin to the plasma mem-
brane than did the vehicle control (Fig. 5 and supplemental Fig.
S5, B and C). This finding suggests that the Ca2-independent
deposition of junction components induced by AMPK activa-
tion requires the nectin-afadin system. To our surprise, how-
ever, in afadin knockdown cells, both SB216763 and LiCl treat-
ments were still able to relocalize significantly more ZO-1 and
occludin to the sites of cell-cell contact compared with their
respective DMSO and NaCl controls. There was no significant
difference in the quantity of ZO-1 or occludin relocalized in
response to GSK-3 inhibition in afadin knockdown cells ver-
sus control cells (Fig. 5 and supplemental Fig. S5, B and C),
suggesting that GSK-3 inhibition induces deposition of junc-
tion components independent of the nectin-afadin system.
This observation further supports the conclusion that AMPK
activation and GSK-3 inhibition induce Ca2-independent
deposition of junction components via different pathways.
Afadin Is an AMPK Substrate—Recent studies inDrosophila
(54, 55) provide interesting clues as to howAMPK is associated
with the polarization events in epithelial cells. (MRLC) was
demonstrated to be phosphorylated byAMPKboth inDrosoph-
ila and in human cells. In Drosophila lacking AMPK expres-
FIGURE 5. Afadin is required to induce the deposition of junction components via AMPK activation but not via GSK-3 inhibition. A, MDCK cells
transfected with afadin or control shRNAs were incubated in LCM for 16 h followed by replacement of the media with fresh LCM supplemented with 1 mM
AICAR, DMSO, 10 M SB216763, 20 mM NaCl, or 20 mM LiCl. Luc-ctrl, luciferase control. Cells were fixed 2 h after the medium change and immunostained for
ZO-1. Bar, 30 m. B, quantification of ZO-1 relocalization to cell membrane in A. Data are representative of three independent experiments (n 3). Error bars
representmeans S.D. for ZO-1 lengthper cellwithin eachof the four randomlypicked view fields. Theasteriskdenotes significant differences in the indicated
pairs (p 0.05) by Student’s t test.
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sion, phosphorylation of Sqh (the Drosophila homolog of
MRLC) was reduced. Transgenic expression of an activated
phosphomimetic version of Sqh could rescue many aspects of
the epithelial polarity defects found in Ampk mutants, sug-
gesting that AMPK regulates epithelial cell polarization pri-
marily through its phosphorylation of MRLC. We therefore
examined MRLC phosphorylation with an antibody recogniz-
ing phosphorylated human MRLC in Ca2-depleted MDCK
cells treated with AICAR. We did not observe any change in
MRLC phosphorylation in response to the treatment, suggest-
ing that MRLC is not likely to be a downstream target for
AMPK in inducing Ca2-independent deposition of junction
components. We also examined MRLC phosphorylation in
MDCK cells subjected to a Ca2 switch. Although AMPK is
activated in this process, we were not able to detect any
concomitant change in the levels of MRLC phosphorylation
(Fig. 6A).
The observation that the knockdown of afadin inhibits the
deposition of junction components induced by AMPK activa-
tion suggests thatAMPK influences afadin function, possibly by
direct phosphorylation. To examine whether or not afadin is an
AMPK substrate, we used an in vitro phosphorylation assay.
We immunoprecipitated endogenous afadin from MDCK cell
lysates, and the immunoprecipitated proteins were then mixed
with recombinant AMPK protein and radioactively labeled
[-32P]ATP, in the presence or absence of an AMPK inhibitor
compound C. After the kinase reactions were terminated, the
proteins eluted from the beads were separated by SDS-PAGE.
The phosphorylation profile was revealed by autoradiography.
We also used an AMPK substrate, SAMS peptide, as a positive
control.We found that recombinant AMPKprotein was able to
incorporate radioactive phosphate groups into the SAMS pep-
tide, and this incorporation was dramatically reduced by com-
pound C (Fig. 6B). The autoradiography profile of the in vitro
phosphorylation assay revealed a band corresponding to the
molecular weight of afadin in samples from the reaction in
which compound C was not included, indicating that afadin
was phosphorylated. In samples in which compound C was
included in the reaction, the intensity of the afadin band was
significantly reduced to a level comparable with that found in
samples from the reactions missing the AMPK recombinant
protein. These data demonstrate that AMPK activity catalyzes
the incorporation of radioactive phosphate groups into afadin
(Fig. 6C) and confirm that afadin is an AMPK substrate in vitro.
We also performed phosphoproteomic studies on afadin
immunoprecipitates prepared from intact MDCK cells to sur-
vey changes in the phosphorylation status of endogenously
expressed afadin. We were able to identify afadin phosphopep-
tides that bear the consensus sequence for AMPK recognition
and phosphorylation (supplemental Table S1). We also found
that the phosphorylation on at least one of these peptides was
substantially increased in cells treatedwith theAMPKactivator
AICAR. These data therefore suggest that afadin is also an
AMPK substrate in vivo (supplemental Fig. S6).
Wenext sought to investigate the functional consequences of
afadin phosphorylation induced by AMPK activation. Because
afadin directly interacts with ZO-1 (32), we hypothesized that
AMPK activation induced by either AICAR treatment or a cal-
cium switch would increase the extent of the interaction
between afadin and ZO-1, thereby facilitating the assembly of
tight junctions. We immunoprecipitated afadin from cells
treated with AICAR, as well as from cells lysed at different time
points following a calcium switch, and then blotted the result-
ing immunoprecipitates to detect ZO-1 that co-precipitated
with afadin. We found that in cells treated with AICAR, more
ZO-1 co-precipitated with afadin compared with that detected
in control cells (Fig. 6D). We also detected increased amounts
of ZO-1 interacting with afadin in cells when the culture con-
ditions were switched from LCM to HCM (Fig. 6E). These
results suggested that AMPK activation might facilitate tight
junction assembly by phosphorylating afadin and inducing or
stabilizing its association with tight junction components such
as ZO-1.
DISCUSSION
We have demonstrated that GSK-3 is involved in the regu-
lation of an important step in epithelial cell polarization. Phar-
macological inhibition of GSK-3 activity leads to the deposi-
tion of junction components to the sites of cell-cell contact in
cells maintained in LCM.We found that AMPK activation and
GSK-3 inhibition independently induce Ca2-independent
deposition of junction components. Furthermore, the deposi-
tion of junction components in response to both treatments is
FIGURE 6. Afadin is an AMPK substrate. A, confluent MDCK cells were incu-
bated in LCM for 16 h and then switched back toHCM for the indicated times.
In addition, a separate set of MDCK cells maintained in LCMwas treated with
1mMAICAR for 2 h. Cells lysateswere probedwith the indicated antibodies in
a Western blot analysis. B, AMPK was incubated with SAMS peptide along
with [-32P]ATP in the presence or absence of compound C (Comp. C). SAMS
peptide incubated in the indicated conditions was subjected to scintillation
counting. C, afadin in MDCK cell lysates was immunoprecipitated (IP), and
AMPKwas then added to the immunoprecipitate alongwith [-32P]ATP in the
presence or absence of compound C. After incubation, proteins were sepa-
rated by SDS-PAGE, and the radioactive signal was detected by autoradio-
graphy. D and E, confluent MDCK cells were incubated in LCM for 16 h then
switched back to HCM for the indicated times (D) or exposed to 1 mM AICAR
for 2 h (E). Cell lysates were immunoprecipitated using an anti-afadin anti-
body. Equal amounts of immunoprecipitates were then separated on SDS-
PAGE and probed for ZO-1. Total cell lysates were simultaneously subjected
to immunoblotting using the anti-afadin and anti-ZO-1 antibodies.
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independent of E-cadherin. We also showed that the nectin-
afadin cell adhesion system is required for the deposition of
junction components induced byAMPK activation, but it is not
required for that induced by GSK-3 inhibition.We have iden-
tified afadin as a substrate for AMPK using an in vitro phosphor-
ylation assay and have shown that it is also phosphorylated in
vivo using phosphoproteomic analysis of intact cells.
We have focused primarily on the Ca2-independent depo-
sition of junction components in this study. To understand how
the kinase activities of GSK-3 and AMPKmight contribute to
this process, it is worth reviewing the biological program
of tight junction assembly, much of which is poorly understood.
The early stages of tight junction assembly are believed to
involve several critical events. First, neighboring cellsmust con-
tact one another, permitting the engagement of cell adhesion
molecules in a trans-interacting manner to form nascent cell
adhesions (56). At this point, signal transduction pathways are
activated that induce cytoskeleton reorganization and large
scale delivery of both tight and adherens junction proteins into
cell membranes (57, 58). The formation of a supporting cyto-
skeleton framework and the clustering of junction proteins
both stabilize and strengthen the nascent cell adhesions. Sub-
sequently, tight junction protein complexes separate from
adherens junctions and move apically to form mature tight
junctions (33). Under normal physiological circumstances, this
process is Ca2-dependent because E-cadherin, themajor arbi-
ter of epithelial cell adhesion, requires Ca2 to actively interact
with its counterpart on a neighboring cell (18).
Our data suggest that, in the processes through which
AMPK activation and GSK-3 inhibition induce the recruit-
ment of tight junction components to the cell surface inde-
pendent of Ca2, the prerequisite for interactions between
E-cadherin molecules on the surfaces of adjacent cells can be
bypassed. This may be achieved by strengthening the trans-
interactions of other cell adhesion molecules, such as those
of the nectin-afadin system, and/or by modulating cytoskel-
eton dynamics near the cell membrane so that nascent cell-
cell contacts are more stable even without the participation
of E-cadherin.
MRLC has emerged as an AMPK effector in regulating
epithelial polarity in recent Drosophila studies (54, 55).
MRLC was reported to be phosphorylated by AMPK in vitro,
and expression of an activated phosphomimetic version of
MRLC could reverse epithelial polarity defects caused by the
loss of AMPK. MRLC has also been reported in many studies
to be implicated in the reorganization of actin cytoskeleton.
Therefore, AMPK could potentially modulate cytoskeleton
dynamics by phosphorylating MRLC and thus regulating its
activity. In our study, however, neither AICAR treatment
nor Ca2 switch induced any change in the level of MRLC
phosphorylation, suggesting that MRLC is not likely an
AMPK target in inducing Ca2-independent deposition of
junction components, at least in the mammalian MDCK cell
system.
We demonstrated that afadin can be phosphorylated by
AMPK, and these findings suggest that afadin is a promising
candidate to serve as the effector of AMPK in inducing junction
assembly. It appears that, when AMPK is activated by AICAR,
afadin plays an essential role in relocalizing tight junction com-
ponents to the sites of cell-cell contact in a Ca2-independent
manner. This conclusion receives support from the fact that
knocking down afadin expression prevented AMPK activation
from inducing Ca2-independent junction assembly. We also
demonstrated that AMPK activation by either AICAR treat-
ment or calcium switch increases the extent of the interaction
between afadin and ZO-1, resulting in a connection between
the nectin-afadin system and the tight junction complex. It is
therefore possible that activation of the nectin-afadin system
might be sufficient on its own to initiate tight junction assem-
bly. In this context, it is interesting to note that nectin junctions
are formed very early in the process of epithelialmorphogenesis
in the developing kidney and that nectin expression occurs
prior to that of the transmembrane tight junction protein
occludin. Furthermore, expression of a dominant negative nec-
tin protein disrupts epithelial cyst formation whenMDCK cells
are grown in three-dimensional collagen gels (30). Taken
together with our findings, these data suggest the interesting
possibility that AMPK may act to initiate or reinforce nectin-
afadin-mediated junction formation at an early stage of cell
junction assembly, after which the formation of fully mature
junctions is carried forward by Ca2 and E-cadherin-depen-
dent processes.
Although a number of recent advances link AMPK with epi-
thelial cell polarity, the role of GSK-3 in the regulation of
cytoskeleton dynamics and cell polarity has not been as exten-
sively studied. In neurons, GSK-3 inhibition ensures the
extension of axons by preventing axonal microtubules from
being disrupted by the GSK-3 substrate CRMP-2. The PI3K
pathway and Akt have been shown to be required for GSK-3
inhibition in this process (43). In migrating astrocytes, Cdc42
and PAR6 promote the activation of atypical PKC at the lead-
ing edge, which consequently phosphorylates and inhibits
GSK-3, leading to the reorganization of cytoskeleton via ade-
nomatous polyposis coli (47, 59).
Although the upstream and downstreammolecules involved
in the deposition of junction components induced by GSK-3
inhibition are still under investigation, our study has provided
some clues in this regard. GSK-3 is known to be inhibited
when its Ser9 residue is phosphorylated by several upstream
kinases such as Akt and atypical PKC. We determined, how-
ever, that although the activity of GSK-3 is inhibited, the level
of GSK-3 Ser9 phosphorylation remained constant during
junction assembly, suggesting that in this process GSK-3 is
inhibited through a mechanism independent of Ser9 phosphor-
ylation and thus independent of its regulation by Akt and atyp-
ical PKC.
In summary, we have identified AMPK andGSK-3 as effec-
tors in novel kinase pathways that lead to the deposition of
junction components without the participation of extracellular
Ca2 or of the Ca2-dependent epithelial cell adhesion
machinery. We also identified afadin as a substrate for AMPK
in this process. Future investigation will be required to identify
the downstream targets of GSK-3, as well as to fully under-
stand the roles that each of these pathways play in junction
formation in vivo.
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